References:

Askanase, A., O. Berkani, C. Cahuzac, P. Cornelisse, D. D'Cruz, K. C. Kalunian, J. T. Merrill, M. Pozzobon and S. Navarra (2022). Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial. ACR Convergence.

European Medicines Agency. (2015). "Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis." Retrieved 09 May, 2024, from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-systemic-lupus-erythematosus-and-lupus-nephritis_en.pdf.

Strasser, D. S., S. Froidevaux, V. Sippel, E. Gerossier, U. Grieder, G. M. Pierlot, A. Kieninger-Graefitsch, E. Vezzali, A. K. Stalder, B. Renault, J. Ryge, A. Hart, U. Mentzel, P. M. A. Groenen, M. P. Keller, M. Trendelenburg, M. M. Martinic and M. J. Murphy (2020). "Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus." RMD Open 6(2).

*The sponsor of the named study is currently Idorsia Pharmaceuticals Ltd. As of March 18, 2024, Viatris entered into a global collaboration with Idorsia, which includes cenerimod, and the study sponsorship is expected to be transferred to Viatris during the course of 2024.

Viatris Middle East FZ-LLC, Atlas Business Center, Floor 6, Al Falak Street, Dubai Media City, Dubai, United Arab Emirates, 502049

© 2024 Viatris Inc. All Rights Reserved.
VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company.